 "Suven gets 3 product patents in Australia, Sri Lanka, South Korea")
Suven Life Sciences Limited, a Hyderabad-based biopharmaceutical company, has received a product patent each from Australia, Sri Lanka and South Korea corresponding to the new chemical entities for the treatment of neuro-degenerative and psychiatric disorders.
These patents are valid till 2029.
In a filing to the BSE on Thursday, Suven Life said the granted claims of the patent included the class of selective 5-HT compounds discovered by Suven and were being developed as therapeutic agents and were used in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s, Huntington’s and Parkinson’s as well as psychiatric ones like Attention Deficiency Hyperactivity Disorder (ADHD) and schizophrenia.
With these new parents, Suven has 16 granted patents from Australia, nine from Sri Lanka and 12 from South Korea. These granted patents are the exclusive intellectual property of Suven. Products out of these innovations might be out-licensed at various phases of clinical development like at Phase-I and Phase-II, the company said.
Suven Life’s scrip is currently trading at Rs 79.75 on the BSE, up 6.19%, over the previous close of Rs 75.10 a share.
These patents are valid till 2029.
In a filing to the BSE on Thursday, Suven Life said the granted claims of the patent included the class of selective 5-HT compounds discovered by Suven and were being developed as therapeutic agents and were used in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s, Huntington’s and Parkinson’s as well as psychiatric ones like Attention Deficiency Hyperactivity Disorder (ADHD) and schizophrenia.
With these new parents, Suven has 16 granted patents from Australia, nine from Sri Lanka and 12 from South Korea. These granted patents are the exclusive intellectual property of Suven. Products out of these innovations might be out-licensed at various phases of clinical development like at Phase-I and Phase-II, the company said.
Suven Life’s scrip is currently trading at Rs 79.75 on the BSE, up 6.19%, over the previous close of Rs 75.10 a share.